Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical ...

Boehringer Ingelheim has slipped another piece of its oncology R&D strategy into place, partnering with Tessellate Bio on a ...

Roche’s Genentech has inked a deal with Repertoire Immune Medicines aimed at discovering and developing T-cell-targeted ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma ...

Market turmoil may have frozen the traditional IPO pipeline, but German antibody biotech Veraxa is turning to the special ...

While Intuitive is still reporting steady growth in the placement of its da Vinci surgical robots—as well as the number of procedures they have performed—the company said it expects to ta | As part of ...

BD is rolling out a new monitoring platform equipped with artificial-intelligence-powered programs that aim to predict ...

Roche’s drug production operations are set to benefit from the company’s updated U.S. strategy, including with “expanded and ...

Biolinq has raised $100 million in venture capital financing to help complete the development of its wearable glucose ...